Dental treatment of patients with leukemia should be planned on the basis of antineoplastic therapy which can be chemotherapy with or without radiotherapy and bone marrow transplantation. Many are the oral manifestations presented by these patients, arising from leukemia and/or treatment. In addition, performing dental procedures at different stages of treatment (before, during, or after) must follow certain protocols in relation to the haematological indices of patients, aimed at maintaining health and contributing to the effectiveness of the results of antineoplastic therapy. Through a literature review, the purpose of this study was to report the hematological abnormalities present in patients with leukemia, trying to correlate them with the feasibility of dental treatment at different stages of the disease. It is concluded in this paper that dental treatment in relation to haematological indices presented by patients with leukemia must follow certain protocols, mainly related to neutrophil and platelet counts, and the presence of the dentist in a multidisciplinary team is required for the health care of this patient.

Caroline Zimmermann

Maria In&#xea;s Meurer

Liliane Janete Grando

Joanita &#xc2;ngela Gonzaga Del Moral

In&#xea;s Beatriz da Silva Rath

Silvia Schaefer Tavares

Dental Treatment in Patients with Leukemia

<i>Objective</i>. The aim of this study was to investigate the prognostic value of <i>MicroRNA-210</i> (<i>miR-210</i>) expression in patients with non-small-cell lung cancer (NSCLC). <i>Methods</i>. We examined the <i>miR-210</i> expression of samples of 80 patients, who underwent surgical resection at Fukushima Medical University from 2004 to 2007, by using quantitative RT-PCR. The relationship between <i>miR-210</i> expression and clinicopathological factors as well as histological subtype was statistically analyzed. <i>Results</i>. <i>miR-210</i> expression showed an inverse correlation with disease-free and overall survival in patients with NSCLC. Significant correlations were found between <i>miR-210</i> expression and lymph node metastasis, late disease stages, and poor prognosis in patients with adenocarcinoma. Multivariate Cox analysis indicated that <i>miR-210</i> expression was an independent prognostic factor for disease-free survival in patients with adenocarcinoma. <i>Conclusions</i>. We showed that <i>miR-210</i> may be a prognostic biomarker for patients with NSCLC, especially for those with lung adenocarcinoma.

Jun Osugi

Yuka Kimura

Yuki Owada

Takuya Inoue

Yuzuru Watanabe

Takumi Yamaura

Mitsuro Fukuhara

Satoshi Muto

Naoyuki Okabe

Yuki Matsumura

Takeo Hasegawa

Athushi Yonechi

Mika Hoshino

Mitsunori Higuchi

Yutaka Shio

Hiroyuki Suzuki

Mitsukazu Gotoh

Prognostic Impact of Hypoxia-Inducible <i>miRNA-210</i> in Patients with Lung Adenocarcinoma

We describe our experience of first 50 consecutive hematopoietic stem-cell transplants (HSCT) done between 2007 and 2012 at the Apollo Hospital, Gandhinagar, 35 autologous HSCT and 15 allogeneic HSCT. Indications for autologous transplant were multiple myeloma, non-Hodgkin lymphoma, Hodgkin lymphoma, and acute myeloid leukemia, and indications for allogeneic transplants were thalassemia major, aplastic anaemia, chronic myeloid leukemia, and acute lymphoblastic and myeloid leukaemia. The median age of autologous and allogeneic patient&#x2019;s cohort was 50 years and 21 years, respectively. Median follow-up period for all patients was 39 months. Major early complications were infections, mucositis, acute graft versus host disease, and venoocclusive disease. All of our allogeneic and autologous transplant patients survived during the first month of transplant. Transplant related mortality (TRM) was 20&#x25; (<i>N</i> = 3) in our allogeneic and 3&#x25; (<i>N</i> = 1) in autologous patients. Causes of these deaths were disease relapse, sepsis, hemorrhagic complications, and GVHD. 46&#x25; of our autologous and 47&#x25; of our allogeneic patients are in complete remission phase after a median follow-up of 39 months. 34&#x25; of our autologous patients and 13&#x25; of our allogeneic patients had disease relapse. Overall survival rate in our autologous and allogeneic patients is 65.7&#x25; and 57.1&#x25;, respectively. Our results are comparable to many national and international published reports.

Chirag A. Shah

Arun Karanwal

Maharshi Desai

Munjal Pandya

Ravish Shah

Rutvij Shah

Hematopoietic Stem-Cell Transplantation in the Developing World: Experience from a Center in Western India

Suwit Duangmano

Phorntip Sae-lim

Apichart Suksamrarn

Pimpicha Patmasiriwat

Frederick E. Domann

Corrigendum to &#x201C;Cucurbitacin B Causes Increased Radiation Sensitivity of Human Breast Cancer Cells via G2/M Cell Cycle Arrest&#x201D;

<i>Background.</i> Currently, few rebiopsies are performed in relapses of advanced non-small cell lung cancer. They are not customary in clinical practice of lung cancer. However, it is not possible to properly target treatments in cases of relapse without knowing the nature of new lesions. <i>Design.</i> This paper comprehensively summarizes the available literature about rebiopsy and broadly discusses the importance of rebiopsy in advanced non-small cell lung cancer. <i>Results.</i> Altogether 560 abstracts were used as material for further analysis. 19 articles were about clinical rebiopsy in lung cancer and were reviewed in detailed manner. <i>Conclusions.</i> This review shows that rebiopsy is feasible in non-small cell lung cancer, and success rates can be high if rebiopsy is accompanied by adequate evaluation before biopsy. Its use may resolve the difficulties in sampling bias and detecting changes in cancer characteristics. In cases where treatment was selected based on tissue characteristics that then change, the treatment selection process must be repeated while considering new characteristics of the tumor. Rebiopsy may be used to predict therapeutic resistance and consequently redirect targeted therapies. Such knowledge may resolve the difficulties in sampling bias and also in selecting preexisting clones or formulating drug-resistant ones. Rebiopsy should be performed more often in non-small cell lung cancer.

Antti P. Jekunen

Role of Rebiopsy in Relapsed Non-Small Cell Lung Cancer for Directing Oncology Treatments

Metastatic renal cell carcinoma with sarcomatoid histology (SmRCC) is associated with poor survival. No data is available from randomized trials on the efficacy of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) inhibitors in SmRCC. We identified SmRCC patients from a single institutional database. To identify predictive and prognostic biomarkers, immunohistochemistry (IHC) analysis was performed on the tumor samples for downstream targets of VEGF and mTOR pathways. Survival outcomes were stratified by IHC analysis, extent of sarcomatoid component, Memorial Sloan-Kettering Cancer Center (MSKCC), and Heng risk criteria. Twenty-seven patients with SmRCC were included. First line therapy included targeted therapy (<svg xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" style="vertical-align:-0.2130003pt" id="M1" height="8.91176pt" version="1.1" viewBox="-0.0498162 -8.69876 35.534 8.91176" width="35.534pt"><g transform="matrix(.0135,0,0,-0.0135,0,0)"><path id="g113-111" d="M495 86L479 114C446 82 419 66 409 66C401 66 401 72 406 97C420 166 436 231 453 297C489 435 454 448 428 448C406 448 384 439 354 422C305 394 222 327 161 247H159L183 345C200 415 194 448 173 448C143 448 82 410 23 351L38 325C64 349 95 371 105 371C111 371 116 365 109 336L25 -4L31 -12C50 -4 77 3 107 9C119 69 132 122 145 168C197 254 321 381 370 381C387 381 393 374 378 305L329 95C309 17 320 -12 345 -12C372 -12 430 19 495 86Z"/></g><g transform="matrix(.0135,0,0,-0.0135,10.586,0)"><path id="g117-34" d="M535 323V373H52V323H535ZM535 138V188H52V138H535Z"/></g><g transform="matrix(.0135,0,0,-0.0135,22.324,0)"><path id="g113-50" d="M384 0V27C293 34 287 42 287 114V635C232 613 172 594 109 583V559L157 557C201 555 205 550 205 499V114C205 42 199 34 109 27V0H384Z"/></g><g transform="matrix(.0135,0,0,-0.0135,28.827,0)"><path id="g113-58" d="M244 635C114 635 38 519 38 422C38 317 111 240 217 240C236 240 255 244 277 256L345 292C311 140 203 39 59 15L64 -15C89 -15 150 -5 204 17C339 72 440 202 440 386C440 521 368 635 244 635ZM228 602C326 602 352 479 352 390C352 370 351 347 348 324C327 308 293 296 258 296C174 296 124 369 124 458C124 517 152 602 228 602Z"/></g></svg>), immunotherapy (<svg xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" style="vertical-align:-0.2130003pt" id="M2" height="8.91176pt" version="1.1" viewBox="-0.0498162 -8.69876 29.0065 8.91176" width="29.0065pt"><g transform="matrix(.0135,0,0,-0.0135,0,0)"><use xlink:href="#g113-111"/></g><g transform="matrix(.0135,0,0,-0.0135,10.586,0)"><use xlink:href="#g117-34"/></g><g transform="matrix(.0135,0,0,-0.0135,22.324,0)"><path id="g113-53" d="M456 178V225H360V632H320C217 496 115 347 20 206V178H280V106C280 40 276 34 189 27V0H445V27C364 34 360 39 360 106V178H456ZM280 225H82C149 335 214 431 278 520H280V225Z"/></g></svg>), cytotoxic chemotherapy (<svg xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" style="vertical-align:-0.2130003pt" id="M3" height="8.91176pt" version="1.1" viewBox="-0.0498162 -8.69876 29.0065 8.91176" width="29.0065pt"><g transform="matrix(.0135,0,0,-0.0135,0,0)"><use xlink:href="#g113-111"/></g><g transform="matrix(.0135,0,0,-0.0135,10.586,0)"><use xlink:href="#g117-34"/></g><g transform="matrix(.0135,0,0,-0.0135,22.324,0)"><use xlink:href="#g113-50"/></g></svg>), and no treatment (<svg xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" style="vertical-align:-0.2130003pt" id="M4" height="8.91176pt" version="1.1" viewBox="-0.0498162 -8.69876 29.0065 8.91176" width="29.0065pt"><g transform="matrix(.0135,0,0,-0.0135,0,0)"><use xlink:href="#g113-111"/></g><g transform="matrix(.0135,0,0,-0.0135,10.586,0)"><use xlink:href="#g117-34"/></g><g transform="matrix(.0135,0,0,-0.0135,22.324,0)"><path id="g113-52" d="M285 378C315 398 338 416 353 432C373 451 384 474 384 503C384 579 325 635 236 635H235C182 635 136 610 108 579L65 516L85 496C110 533 150 575 205 575C258 575 300 543 300 481C300 407 232 369 141 339L147 310C163 315 188 321 211 321C268 321 338 284 338 192C338 94 288 40 217 40C160 40 119 68 93 91C85 98 77 97 69 91C60 84 47 71 46 58C44 46 48 35 62 22C75 10 116 -12 162 -12C234 -12 424 62 424 224C424 297 373 359 285 376V378Z"/></g></svg>). Median OS was 8.2 months (95&#x25; CI 3.8&#x2013;14.2 months). Median survival in months, based on MSKCC and Heng risk groups, was favorable 89.3 versus 84.5, intermediate 9.5 versus 12.7, and poor 3.9 versus 5.1. None of the IHC markers predicted outcomes of treatment with VEGF or mTOR inhibitors. Only tumor IMP3 expression was associated with inferior OS, although not statistically significant (IMP3 negative 14.2 versus IMP3 positive 4.9 months; HR 0.46, 95&#x25; CI 0.16&#x2013;1.21; <svg xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" style="vertical-align:-0.2129908pt" id="M5" height="9.21094pt" version="1.1" viewBox="-0.0498162 -8.99795 46.7259 9.21094" width="46.7259pt"><g transform="matrix(.0135,0,0,-0.0135,0,0)"><path id="g113-81" d="M600 480C600 590 528 650 384 650H143L137 622C222 614 225 607 210 531L130 127C113 41 106 36 23 28L17 0H294L300 28C204 36 195 42 212 127L243 284L314 263C327 263 339 263 352 264C465 271 600 337 600 480ZM508 481C508 351 402 304 329 304C289 304 265 311 250 317L295 559C302 594 310 606 323 611C335 616 350 619 367 619C455 619 508 573 508 481Z"/></g><g transform="matrix(.0135,0,0,-0.0135,12.15,0)"><use xlink:href="#g117-34"/></g><g transform="matrix(.0135,0,0,-0.0135,23.887,0)"><path id="g113-49" d="M241 635C89 635 35 457 35 312C35 153 89 -12 240 -12C390 -12 443 166 443 312C443 466 390 635 241 635ZM238 602C329 602 354 454 354 312C354 172 330 22 240 22C152 22 124 173 124 313S148 602 238 602Z"/></g><g transform="matrix(.0135,0,0,-0.0135,30.39,0)"><path id="g113-47" d="M113 -12C146 -12 170 11 170 46C170 78 146 103 114 103S58 78 58 46C58 11 82 -12 113 -12Z"/></g><g transform="matrix(.0135,0,0,-0.0135,33.48,0)"><use xlink:href="#g113-50"/></g><g transform="matrix(.0135,0,0,-0.0135,39.983,0)"><path id="g113-51" d="M412 140C382 77 369 73 315 73H129L270 222C362 320 402 379 402 466C402 571 322 635 234 635C177 635 130 609 99 576L42 495L64 475C90 514 133 568 201 568C274 568 318 519 318 435C318 349 255 267 193 193C144 135 87 78 32 23V0H405C417 45 427 89 440 131L412 140Z"/></g></svg>). The study was limited by small sample size.

Srinivas K. Tantravahi

Daniel Albertson

Archana M. Agarwal

Sowmya Ravulapati

Austin Poole

Shiven B. Patel

Jamil S. Hawatmeh

Alli M. Straubhar

Ting Liu

David D. Stenehjem

Neeraj Agarwal

Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma

About this journal

<p><em>Journal of Oncology</em> publishes research related to breast cancer, lung cancer, gastrointestinal cancer, skin cancer, head and neck cancer, paediatric oncology, neurooncology as well as genitourinary cancer.</p>


Journal profile

Meet the editorial board

<p>Chief Editor, Professor Bruno Vincenzi, is an Associate Professor of Medical Oncology at University Campus Bio-Medico, Italy. His research interests include urogenital neoplasms and the pathophysiology and treatment of bone metastases.</p>


Editor spotlight

Submit to Special Issue

We currently have a number of Special Issues open for submission. Special Issues highlight emerging areas of research within a field, or provide a venue for a deeper investigation into an existing research area.

Special Issues

Author guidelines

Editorial board

Databases and indexing

Journal of Oncology - Table of contents 2015

title

Journal of Oncology publishes research related to breast cancer, lung cancer, gastrointestinal cancer, skin cancer, head and neck cancer, paediatric oncology, neurooncology as well as genitourinary cancer.

Journal of Oncology